Clinical Trials Logo
  1. Home
  2. Endophthalmitis
  3. NCT01323868
  4. Details
NCT01323868 Clinical Trial

Endogenous Endophthalmitis in the Inpatient Setting

Endophthalmitis Clinical Trial

Official title:
Endogenous Endophthalmitis Rates, Clinical Course, and Outcomes

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01323868
Other study ID # SU-03232011-7621
Secondary ID IRB-18785
Status Completed
Phase N/A
First received March 24, 2011
Last updated November 17, 2014
Start date July 2010
Est. completion date June 2013

Study information
Verified date November 2014
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this study is to determine the rate of endogenous endophthalmitis in patients admitted to Stanford Hospital with a systemic infection and positive blood cultures, as this may improve the clinical care of this population of patients.

Description:

Some patients admitted to the hospital have blood-borne infections. Occasionally, these blood infections can end up inside the eye and cause an infection inside the eye (called endogenous endophthalmitis).

Prior to modern and rapid treatment of systemic infections, the rate of endogenous endophthalmitis was reported to be 37% in 1982. By 1997, the rate was reported to be 2.8%. This study aims to determine the rate of endogenous endophthalmitis at Stanford Hospital in the modern medical era in that our rates may be different as those reported in the literature. This potential difference may be a reflection of treatment protocols and antibiotics currently in use at Stanford Hospital.

Recruitment information / eligibility
Status Completed
Enrollment 145
Est. completion date June 2013
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:All patients admitted to Stanford Hospital that have a systemic blood-borne infection and on which an Ophthalmology consult to rule out endogenous endophthalmitis is performed will be included in the study.

Exclusion Criteria:None

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
United States Stanford University School of Medicine Stanford California

Sponsors (1)
Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Positive intraocular infection 1 day No
Secondary Visual acuity 2 wk No
See also
  Status Clinical Trial Phase
Recruiting NCT04214821 - The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% Phase 1/Phase 2
Completed NCT00461656 - Povidone-iodine Antisepsis for Strabismus Surgery Phase 4
Completed NCT00136344 - Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery N/A
Completed NCT04568213 - Hypochlorous Acid Disinfection Prior to Cataract Surgery Phase 3
Terminated NCT01496794 - Endophthalmitis Cultures N/A
Completed NCT00406913 - Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery N/A
Recruiting NCT05079854 - Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis Phase 4
Recruiting NCT05432336 - Complex Ocular Infection, Optimization of Microbiological Diagnosis
Recruiting NCT02810587 - Endophthalmitis After Intravitreous Anti-VEGF Injections in Patients Receiving vs. Not Receiving Topical Antibiotics N/A
Completed NCT00398658 - Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis Phase 4
Recruiting NCT04035369 - Endophthalmitis Post Intravitreal Injections N/A
Not yet recruiting NCT03420820 - Concentrating on Antisepsis: 5% vs. 10% Povidone-Iodine Prior to Intravitreal Injection N/A
Recruiting NCT06268561 - Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months
Withdrawn NCT00335231 - Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery N/A
Not yet recruiting NCT03244072 - Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery Phase 2/Phase 3
Completed NCT03363295 - Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis Phase 4
Suspended NCT02590523 - Intracameral Antibiotic Safety Study Phase 3
Terminated NCT02770729 - Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis. Phase 3
Not yet recruiting NCT02324166 - Cefazolin-Lidocaine Combination Solution to Reduce Antibiotic Pain Phase 4
Completed NCT02595359 - Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis Phase 2